Kinex Pharmaceuticals Selects Lead Drug Candidate for Clinical Development in Oncology
Posted on: Tuesday, 6 September 2005, 09:01 CDT
BUFFALO, N.Y., Sept. 6 /PRNewswire/ -- Kinex Pharmaceuticals, a biopharmaceutical company developing small molecule drugs for the treatment of cancer, announced today that KX2-377 has been selected as a lead drug candidate for clinical development. The compound -- which was discovered based upon the company's proprietary technology platform -- is a potent, orally available, and highly selective small molecule that inhibits Src kinase phosphorylation. Src kinase plays a key role in tumor growth and metastasis. KX2-377 is unique in that it was designed to target the substrate pocket of Src kinase instead of the ATP pocket, reported by others.
"This compound-KX2-377-has demonstrated an excellent pharmacokinetic profile. We have encountered no safety problems thus far, and its unique properties provide opportunities for both anticancer treatment and maintenance therapy," said Dr. Allen Barnett, Chief Executive Officer of Kinex Pharmaceuticals. Barnett added, "We are extremely enthusiastic about the progress we are making to advance this promising new class of drug candidates into the clinic. The combination of our exclusive platform technology and demonstrated drug discovery and development experience has allowed us to move both the technology and lead drug discovery/development forward in a highly efficient manner. As a result, we believe Kinex will be first in class and first to market with this next-generation anti-cancer drug that targets the substrate pocket of Src kinase."
The Company is preparing for an Investigational New Drug (IND) application and planning for submission to the United States Food and Drug Administration (FDA) during the second quarter of 2006.
About Kinex Pharmaceuticals, LLC
Kinex Pharmaceuticals
For additional information, contact: Allen Barnett, Ph.D. Chief Executive Officer Kinex Pharmaceuticals, LLC 1207 Delaware Avenue Buffalo, New York 14209 716.332.6107
Kinex Pharmaceuticals
CONTACT: Allen Barnett, Ph.D., Chief Executive Officer of KinexPharmaceuticals, LLC, +1-716-332-6107
Web site: http://www.kinexpharma.com/
Source: PRNewswire
Related Articles
- Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
- Excaliard Pharmaceuticals Appoints Lincoln Krochmal, MD, President & Chief Executive Officer and Jeffrey Jenson, Head of Clinical Operations.
- Znomics Appoints Pharmaceutical Drug Discovery Expert, Bruce A. Beutel, Ph.D., As New Chief Scientific Officer
- Shot in the Arm: South Korean Government Promises a Hike in Drug and Pharmaceutical R&D Expenditure
- Affinium Pharmaceuticals Welcomes Dr. Barry Hafkin As Chief Medical Officer
- Nereus Pharmaceuticals Appoints Dr. Charles White As Chief Business Officer
- Proprius Pharmaceuticals Appoints David W. Anderson, Ph.D. As Chief Scientific Officer
- AVEO Pharmaceuticals Appoints John Ryan, Ph.D., M.D., As Chief Medical Officer
- BroadSoft Selected By TelCove to Support Network-Based VoIP Services Over Fiber; BroadWorks Application Platform Powers TelCove's High-Quality VoIP Services
- Cancer Drugs Drive Pharmaceutical Success, Claim Marketing Dollars
 |
 |
User Comments (0)
RSS Feeds